/[corp_html]/multi/Pipeline.htm
This is repository of my old source code which isn't updated any more. Go to git.rot13.org for current projects!
ViewVC logotype

Contents of /multi/Pipeline.htm

Parent Directory Parent Directory | Revision Log Revision Log


Revision 1.1 - (show annotations)
Thu Jul 25 13:08:36 2002 UTC (21 years, 8 months ago) by dpavlin
Branch: MAIN
CVS Tags: HEAD
File MIME type: text/html
new

1
2 <p align="left"><font size="4" color="#FF9933"><b><img src="t/development.gif" width="225" height="16"></b></font></p>
3 <table width="90%" border="0" cellspacing="0" cellpadding="0" align="center">
4 <tr>
5 <td height="10" width="19%">
6 <div align="center"><b>PROJECT</b></div>
7 </td>
8 <td height="10" width="26%">
9 <div align="center"><b>INDICATION</b></div>
10 </td>
11 <td height="10" width="24%">
12 <div align="center"><b>STATUS</b></div>
13 </td>
14 </tr>
15 </table>
16 <table width="90%" border="1" cellspacing="0" cellpadding="0" align="center">
17 <tr>
18 <td width="19%">
19 <div align="center">PLD - 116</div>
20 </td>
21 <td width="26%">
22 <div align="center">Inflammatory Bowel Disease (IBD)</div>
23 </td>
24 <td width="24%">
25 <div align="center">Clinical Trials</div>
26 </td>
27 </tr>
28 <tr>
29 <td width="19%">
30 <div align="center">PLD - 117</div>
31 </td>
32 <td width="26%">
33 <div align="center">Oncology<br>
34 Hematology</div>
35 </td>
36 <td width="24%">
37 <div align="center">Clinical Trials</div>
38 </td>
39 </tr>
40 <tr>
41 <td width="19%">
42 <div align="center">PLD - 118</div>
43 </td>
44 <td width="26%">
45 <div align="center">Anti-fungal</div>
46 </td>
47 <td width="24%">
48 <div align="center">Clinical Trials</div>
49 </td>
50 </tr>
51 <tr>
52 <td width="19%">
53 <div align="center">PLR - 1</div>
54 </td>
55 <td width="26%">
56 <div align="center">Anti-infective</div>
57 </td>
58 <td width="24%">
59 <div align="center">Discovery</div>
60 </td>
61 </tr>
62 <tr>
63 <td width="19%">
64 <div align="center">PLR - 13</div>
65 </td>
66 <td width="26%">
67 <div align="center">Inflammation<br>
68 Asthma</div>
69 </td>
70 <td width="24%">
71 <div align="center">Discovery</div>
72 </td>
73 </tr>
74 <tr>
75 <td width="19%">
76 <div align="center">PLR - 9</div>
77 </td>
78 <td width="26%">
79 <div align="center">Anti-infective</div>
80 </td>
81 <td width="24%">
82 <div align="center">Discovery</div>
83 </td>
84 </tr>
85 <tr>
86 <td width="19%">
87 <div align="center">PLR - 14</div>
88 </td>
89 <td width="26%">
90 <div align="center">Inflammation<br>
91 RA, IBD</div>
92 </td>
93 <td width="24%">
94 <div align="center">Discovery</div>
95 </td>
96 </tr>
97 </table>
98
99
100 <p><b>PLD-116</b></p>
101 <p>Full Phase I clinical studies of PLD-116 were successfully completed in the EU in the first half of 2001. PLD-116 treatment proved to be well tolerated in thirty-two healthy volunteers. The PLD-116 project was initiated in December 1999 to develop a novel peptide into a drug for the treatment of inflammatory bowel disease. The peptide, derived from a natural protein, provides a novel anti-inflammatory treatment option for inflammatory bowel disease.</p>
102 <p><b>PLD-117</b></p>
103 <p>In 1999 PLIVA signed a licensing agreement with <a
104 href="http://www.receptron.com">Receptron, Inc.</a>, a
105 Californian based Biotech Company, and acquired exclusive worldwide rights to
106 develop and market the PLD-117 peptide with TPO-like activity. The
107 peptide PLD-117 for the treatment of thrombocytopenia, a severe complication
108 of cancer chemotherapy, was brought to clinical study trials in the USA in December
109 2000. The proposed treatment is based on a unique approach using peptide that
110 activates thrombopoietin (TPO) receptor.</p>
111 <p><b>PLD-118</b></p>
112 <p>The licensed-in novel antifungal agent PLD-118 was successfully brought into clinical development ahead of schedule in November 2000. Two Phase I clinical studies of PLD-118 were successfully completed in the EU in August 2001. PLD-118 has the potential to be the first novel oral antifungal for the treatment of Candida infections since the introduction of azoles in the 80's.</p>

  ViewVC Help
Powered by ViewVC 1.1.26